%D9%86%D9%8A%D9%81%D9%88%D9%84%D9%88%D9%85%D8%A7%D8%A8NivolumabNivolumabNivolumabNivolumab%D9%86%DB%8C%D9%88%D8%A7%D9%84%DB%8C%D9%88%D9%85%D8%A8Nivolumab%E3%83%8B%E3%83%9C%E3%83%AB%E3%83%9E%E3%83%96%EC%98%B5%EB%94%94%EB%B3%B4NivolumabNiwolumabNivolumabQ7041828%E7%BA%B3%E6%AD%A6%E5%88%A9%E5%B0%A4%E5%8D%95%E6%8A%97
about
sameAs
non-Hodgkin lymphomarenal cell carcinomaMerkel cell carcinomasquamous cell carcinoma of the lungmelanomahead and neck squamous cell carcinomacolon cancerbenign mesotheliomabronchus carcinomarenal clear cell carcinomaanal carcinomabenign pleural mesotheliomahematologic cancerlymphomatransitional cell carcinomadiffuse large B-cell lymphomaacute myeloid leukemiatongue squamous cell carcinomakidney cancernon-small-cell lung carcinomabladder cancermetastatic melanomasecondary neoplasmmyelodysplastic syndrome
P2176
P3781
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerEvaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip PlatformNivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by SurgeryTrial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaTrial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG ImmunotherapyNivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerAn Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell CarcinomaDA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLCMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseREACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric CancerPhase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorSitravatinib and Nivolumab in Urothelial Carcinoma StudyDexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple MyelomaNivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III MeningiomapTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerNivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid LeukemiaStudy of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic CancerA Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in JapanCost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has SpreadEvaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaStudy to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in MexicoStudy of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsNivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerAn Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsA Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseCBT-501 or Nivolumab in Combination With CBT-101 in Locally Advanced or Metastatic HCC and RCCAbemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based ChemotherapyIRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver CancerAfatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckTreatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic CancerModified FOLFOX Plus/Minus Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerModulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerIpilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaTrial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCNivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerPD-(L)1 Inhibitors With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung CancerA Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
P4844
Nivolumab plus ipilimumab in advanced melanoma.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerEpidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case reportTargeting Multiple Receptors to Increase Checkpoint Blockade EfficacyCharacterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenograftsProliferative potential and resistance to immune checkpoint blockade in lung cancer patientsClinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerRisk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patientsPredictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary reportA case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiencyEfficacy and safety of nivolumab for metastatic biliary tract cancerImmune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapyPericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two CasesNivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging DiagnosisBaseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumabNivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal CancerA phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapyCheckpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case seriesSuccessful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case reportManaging cardiotoxicity associated with immune checkpoint inhibitorsTransient eruptive keratoacanthomas associated with nivolumabPD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature ReviewRadiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumabAdverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective StudyEarly assessment with F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumabAssociation of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced MelanomaManagement of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical GuidelinesImmune checkpoint inhibitors in malignancyPosterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancerReal-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumImmune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed TomographyProlonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinomaEGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negativeImproved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patientsGustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung CancerQ64100367
P921
Q1138590-C3315C0E-128A-4046-A866-58A718E660D8Q1164529-54025E53-1448-4C59-9A53-F1F6EB1CA54FQ1711744-029CF859-05BC-4EC2-AB30-55B29ACF5BD5Q17148386-34611AFD-77B8-404C-ACB8-73C350CFD8FDQ180614-10A39C4E-1D98-4953-8FDE-37178F082A00Q18348812-91B38ED5-C314-443D-8C0C-D6E5CE45E871Q18555025-A6DD68E8-91A2-49DC-BA60-DD5D5A653589Q18555143-02BF1FCC-E3BD-413D-A82E-79A727D7A1D5Q18556109-EA6B4739-BD7F-4664-B678-074784A2256BQ18556340-2D4F04FB-4A69-473A-803F-DF4B7DEF371BQ18556540-79E3DAC3-7B74-4688-AB25-7971E97FDDD0Q18556653-A6653761-6A5F-461A-A28D-45DEC8A20849Q18975047-175574C1-DBA2-46DD-B9A4-9C9BB91AB911Q208414-8324DDBD-AFE4-43BB-9E85-4B32CC200EEDQ2501186-C4482889-BCFB-40B7-9825-3500065D61EBQ2626074-9DDC547D-4C95-42B8-9058-379C2D8C489BQ264118-411299DF-95BD-46C0-A878-335BB02E23D8Q28757362-DF970C08-EB69-4E65-85D3-F627A87A41D8Q3242950-D4E6CEBD-375C-4AEE-8015-24CB52403E5DQ3658562-51982F93-F45C-4B18-BC1A-A0E02C703250Q504775-3ABFF736-768B-4D88-8015-55AEB94F20D5Q55779849-B4439A5D-EF11-4FEA-B246-6CDD42C32C6DQ55790826-B5289502-9281-4456-B4B8-A528FA3DCECEQ954625-36FB37EF-EDAC-420A-B983-6569C5DCDA61
P2176
description
chemická sloučenina
@cs
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
compuesto quimico
@an
name
Nivolumab
@de
Nivolumab
@el
Nivolumab
@es
Nivolumab
@nb
Nivolumab
@pl
Nivolumab
@vi
nivolumab
@cs
nivolumab
@en
nivolumab
@fr
nivolumab
@nl
type
label
Nivolumab
@de
Nivolumab
@el
Nivolumab
@es
Nivolumab
@nb
Nivolumab
@pl
Nivolumab
@vi
nivolumab
@cs
nivolumab
@en
nivolumab
@fr
nivolumab
@nl
altLabel
BMS-936558
@en
BMS-936558
@nn
BMS-936558
@pl
MDX-1106
@en
MDX-1106
@nn
MDX-1106
@pl
ONO-4538
@en
ONO-4538
@nn
ONO-4538
@pl
anti-PD-1
@de
prefLabel
Nivolumab
@de
Nivolumab
@el
Nivolumab
@es
Nivolumab
@nb
Nivolumab
@pl
Nivolumab
@vi
nivolumab
@cs
nivolumab
@en
nivolumab
@fr
nivolumab
@nl
P2175
P31
P672
P486
P592
P6366
P665
P672
P2115
N0000191289
P2175
P2275
Nivolumab
@en
P231
946414-94-4
P267
P2868
P3345
P3780
P486
D000077594
P592
CHEMBL2108738
P6366
2780030458
P652
31YO63LBSN
P665
P672
D12.776.124.486.485.114.224.060.829
D12.776.124.790.651.114.224.060.829
D12.776.377.715.548.114.224.200.829